Precigen, Inc.
PGEN
Rank in Stocks
#6538
Precigen, Inc. is an American company dedicated to the discovery and... Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Share Price
$4.73
Last synced: 2026-11-09
Market Cap
$1.69B
Change (1 day)
5.82%
Change (1 year)
17.66%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Precigen, Inc. (PGEN)
Category
Healthcare
EPS for Precigen, Inc. (PGEN)
EPS as of September 2026 TTM: $0.07
According to Precigen, Inc.'s latest financial reports, its current EPS (TTM) is $0.07. At the end of 2025 the company had an EPS of $-1.41, a decrease compared to its 2024 EPS of $-0.47.
EPS history for Precigen, Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.07 | -104.84% |
| 2025 | $-1.41 | 200.00% |
| 2024 | $-0.47 | 20.51% |
| 2023 | $-0.39 | 18.18% |
| 2022 | $-0.33 | -29.79% |
| 2021 | $-0.47 | -53.92% |
| 2020 | $-1.02 | -24.44% |
| 2019 | $-1.35 | -65.65% |
| 2018 | $-3.93 | 301.02% |
| 2017 | $-0.98 | -37.97% |
| 2016 | $-1.58 | 107.89% |
| 2015 | $-0.76 | -8.43% |
| 2014 | $-0.83 | -12.63% |
| 2013 | $-0.95 | -93.58% |
| 2012 | $-14.80 | -1.66% |
| 2011 | $-15.05 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 22,828.26% |
US
|
|
| $-7.07 | -10,451.39% |
US
|
|
| $-5.29 | -7,845.24% |
AU
|
|
| $12.88 | 18,758.13% |
BE
|
|
| $21.56 | 31,466.62% |
NL
|
Questions about Precigen, Inc.'s earnings per share (EPS)
What is Precigen, Inc.'s earnings per share (EPS)?
Precigen, Inc.'s earnings per share (EPS) over the last twelve months is $0.07, as of Sep 2026.
What was Precigen, Inc.'s earnings per share (EPS) in 2025?
In 2025, Precigen, Inc.'s earnings per share (EPS) was $-1.41, compared with $-0.47 in 2024.
How has Precigen, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Precigen, Inc.'s earnings per share (EPS) was highest in 2022 ($-0.33) and lowest in 2025 ($-1.41).
How does Precigen, Inc.'s earnings per share (EPS) compare with similar companies?
Precigen, Inc.'s earnings per share (EPS) ($0.07) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.